Balance Sheet Details (Tables)

6 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Inventory

Inventory consisted of the following (in thousands):

	June 30, 2024		December 31, 2023
Finished goods	$	17,205	$	5,001
Work in process		5,361		4,134
Raw material		63,503		31,312
	$	86,069	$	40,447
Reported as:
Inventory	$	71,525	$	35,819
Long-term inventory		14,544		4,628
Total	$	86,069	$	40,447

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	June 30, 2024		December 31, 2023
Accrued sales allowances	$	126,493	$	90,718
Accrued contingent payments		79,583		29,583
Accrued research and development services		26,059		32,883
Accrued compensation and benefits		26,044		42,718
Accrued consulting and professional fees		24,152		18,804
Current portion of lease liabilities		10,470		9,405
Accrued royalties		8,456		8,710
Current portion of accrued branded prescription drug fees		7,836		718
Other		8,876		3,172
	$	317,969	$	236,711